BridgeBio Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)
The following documents are filed as part of this Annual Report on Form 10‑K:
Financial Statements:
The following financial statements and schedules of the Registrant are contained in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10‑K:
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm | 139 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 142 |
| Consolidated Statements of Operations for of the three years in the period ended December 31, 2023 | 143 |
| Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 2023 | 144 |
| Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders’ Equity (Deficit) for each of the three years in the period ended December 31, 2023 | 145 |
| Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023 | 146 |
| Notes to Consolidated Financial Statements | 148 |
Financial Statement Schedules:
All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.
(b)
Exhibits required by Item 601 of Regulation S‑K:
The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.